"Bicalutamid, 150 mg, er indiceret til patienter med lokal avanceret prostatacancer med høj risiko for progression af sygdommen, enten som eneste behandling eller som adjuverende behandling til radikal prostatektomi eller strålebehandling".
The Committee, considering the Casodex Referral (bicalutamide 150 mg) made under article 31 of Directive 2001/ 83/ EC for medicinal products containing bicalutamide, reached the conclusion that bicalutamide 150mg is effective in the treatment of locally advanced prostate cancer; however the CHMP considered that the therapeutic indication should be restricted to: “ Bicalutamide 150mg is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression”.